Skip to content
WyteRock E-Books

WyteRock Blog

Peptides on TikTok: what the evidence says about BPC-157 and the new US compounding policy

WyteRock Global · 2026-11-01

Peptide injections are among the most visible health trends of 2026, and in late October two events put them in the headlines: TikTok restricted searches for several peptide names, and the US Department of Health and Human Services said it would not act against licensed pharmacies that compound six unapproved peptides. Neither event is evidence that the products work. The human data for the best-known of them, BPC-157, remain very thin.

Peptides are short chains of amino acids. The word covers established, approved medicines such as insulin and semaglutide, and also experimental compounds that no regulator anywhere has approved for human use. Online, the two groups are often discussed as if they were one. A JAMA Viewpoint published in June 2026 reported that peptide-related hashtags had passed 230 million TikTok views and 130,000 Instagram posts by May 2026, and described synthetic peptides as "a new frontier in enhancement drug use". The compounds most often promoted are injectables such as BPC-157 and TB-500, marketed for recovery from injury, muscle growth and anti-ageing.

What happened in October

TikTok search restrictions. On 20 October 2026, The Verge reported that TikTok searches for terms including BPC-157, retatrutide and semaglutide returned no results. Follow-up coverage noted that the general term "peptides" still returned many videos and that existing videos did not appear to have been removed. TikTok has not published a list of the restricted terms.

The US compounding policy. On 28 October 2026, HHS filed a notice, published in the Federal Register on 30 October, announcing an "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances". Under it, HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Reported conditions include sourcing from an FDA-registered facility, a valid certificate of analysis, and reporting of serious adverse events and quality problems to the FDA. The notice describes the document as a draft, opens a two-week comment period on Docket HHS-OASH-2026-0496, and states that HHS may revisit the policy if a safety signal or product-quality issue arises. It applies until the FDA settles, through rulemaking, which substances belong on the "503A bulks list" of ingredients that pharmacies may compound.

How the policy came about

In July 2026 the FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides. The FDA's own briefing document proposed that none of the seven be added to the list. For each, FDA staff recommended against inclusion, citing a lack of clinical evidence of safety and efficacy. The committee voted the other way on six of them: 8–6 for BPC-157 (for ulcerative colitis), KPV and TB-500, 7–5 for MOTS-c, and in favour of Semax and Epitalon the following day. It rejected Emideltide by a narrow vote. Advisory votes are not binding, and the October policy was issued before any formal rulemaking.

What the evidence says

The central point is simple: permission to compound is not proof of benefit. The notice itself states that compounded drugs are not FDA-approved, "which means FDA does not review their safety, effectiveness, or quality before they are marketed".

For BPC-157, the most widely promoted of the six, the published evidence is overwhelmingly from animals:

  • A systematic review in HSS Journal (Vasireddi et al., 2025) searched PubMed, Cochrane and Embase to June 2024. Of 36 included studies, 35 were preclinical and one was clinical. That single human study was retrospective: 7 of 12 patients with chronic knee pain reported relief lasting more than six months after an injection. The authors found no clinical safety data and noted that adverse effects are possible because of unregulated manufacturing, contamination or unknown safety.
  • A review in Current Reviews in Musculoskeletal Medicine (McGuire et al., 2025) found only three small human pilot studies, described human data as "extremely limited", and concluded that BPC-157 should be treated as investigational until well-designed trials exist.

Animal results are a reason to run trials, not a substitute for them. Many compounds that heal tendons in rats never show a benefit in people, and rare harms only become visible in large, controlled human studies. Uncontrolled reports of improvement after an injection are also difficult to interpret, because pain from many musculoskeletal injuries improves over time regardless of treatment.

Quality is a separate concern. Much of the peptide supply sold online is labelled "for research use only", which means it was never manufactured or tested as a medicine. HHS itself presents the new policy as a way to discourage the "continued, widespread use of certain research-use-only peptides".

The position in Europe and in sport

The US policy has no effect in the European Union. Under Article 6 of Directive 2001/83/EC, a medicinal product may not be placed on the market of a Member State without a marketing authorisation, and a product counts as a medicine if it is presented as treating or preventing disease or is used to restore, correct or modify physiological functions. BPC-157 is not approved as a therapeutic product in any country, according to the US Anti-Doping Agency, so it cannot lawfully be marketed as a medicine in the EU.

In sport, BPC-157 has been named on the World Anti-Doping Agency's Prohibited List since 2022, under S0 (non-approved substances), and is prohibited at all times, in and out of competition.

What this means for you

For members of the public. A product being widely discussed, or newly tolerated by a regulator, does not mean it has been shown to be safe or effective. The honest summary for BPC-157 today is "promising in animals, essentially untested in people". Anyone considering such a product should discuss it with a doctor who can weigh it against approved treatments, and should be cautious about products sold for "research use only".

For clinicians. Patients will increasingly arrive having seen peptide content. A short, accurate account of the evidence is more persuasive than dismissal. The reviews cited below are a useful starting point.

For companies developing peptides. The commercial interest is real, but durable access in Europe still runs through clinical evidence and a marketing authorisation, not through social-media reach. A well-designed trial that answers a clear clinical question is now a genuine competitive advantage in a field crowded with claims. WyteRock's clinical evidence planning service helps sponsors decide what evidence a product needs and in what order.

For anyone who needs a precise answer. If you need one scoped question settled, such as the regulatory status of a specific peptide in a given market or a summary of the published evidence for a claim, the fixed-price Task Request service is designed for that. US stakeholders who wish to comment on the HHS policy may do so on regulations.gov, Docket HHS-OASH-2026-0496, until 13 November 2026, two weeks after its publication.

Alex Mansour is CEO of WyteRock Global, a France-based life-sciences advisory firm that supports manufacturers, laboratories and investors on clinical evidence planning and EU market access.

Sources

  1. Piatkowski T, Ganson KT, Nagata JM. Illicit Injectable Peptides and Regulatory Gaps. JAMA. 2026;336(3):189–190. doi:10.1001/jama.2026.10690. https://jamanetwork.com/journals/jama/article-abstract/2850449
  2. US Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Notice of availability, Docket HHS-OASH-2026-0496, FR Doc. 2026-22192, filed 28 October 2026, published 30 October 2026. https://www.federalregister.gov/public-inspection/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
  3. US Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, 23–24 July 2026. https://www.fda.gov/media/193342/download
  4. RAPS Regulatory Focus. "HHS will permit compounding of six peptides ahead of formal rulemaking", 29 October 2026. https://www.raps.org/resource/hhs-will-permit-compounding-of-six-peptides-ahead-of-formal-rulemaking.html
  5. STAT. "FDA panel backs compounded BPC-157, KPV peptides", 23 July 2026. https://www.statnews.com/2026/07/23/fda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv/ and "FDA advisory panel narrowly rejects compounding of one peptide, backs two others", 24 July 2026. https://www.statnews.com/2026/07/24/fda-peptide-compounding-panel-backs-epitalon-rejects-emideltide/
  6. Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485–495. doi:10.1177/15563316251355551. https://pubmed.ncbi.nlm.nih.gov/40756949/
  7. McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611–619. doi:10.1007/s12178-025-09990-7. https://pubmed.ncbi.nlm.nih.gov/40789979/
  8. YPulse. "TikTok is making it harder for users to search for peptides", 22 October 2026, reporting The Verge, 20 October 2026. https://www.ypulse.com/newsfeed/2026/10/22/tiktok-is-making-it-harder-for-users-to-search-for-peptides/
  9. Directive 2001/83/EC on the Community code relating to medicinal products for human use, Articles 1(2) and 6(1). EUR-Lex: https://eur-lex.europa.eu/eli/dir/2001/83/oj/eng
  10. US Anti-Doping Agency. "Athlete Advisory: Explanation of Key Changes on 2022 WADA Prohibited List". https://www.usada.org/athlete-advisory/key-changes-2022-prohibited-list/

Get new articles by email. Sign up for the newsletter or join the CentiAgent Club; members receive an alert for every new article.